Saudi Arabia Liver Cancer Therapeutics Market Report 2022 to 2030

Saudi Arabia Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Saudi Arabia Liver Cancer Therapeutics market will reach a value of $201.7 Mn from $49.8 Mn in 2022, growing at a CAGR of 19.1 % during 2022-30. Liver Cancer Therapeutics in Saudi Arabia is dominated by a few domestic pharmaceutical companies such as Jamjoom Pharma, Tabuk Pharmaceuticals, and SPIMACO. The Liver Cancer Therapeutics market in Saudi Arabia is segmented into different types of cancer and different therapy types. Some of the major factors affecting the Saudi Arabia Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10SAPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Dr. Vishwa Modhia

Buy Now

Saudi Arabia Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Saudi Arabia Liver Cancer Therapeutics market will reach a value of $201.7 Mn from $49.8 Mn in 2022, growing at a CAGR of 19.1 % during 2022-30.

Saudi Arabia is a high-income, developing country in the Middle East bordering the Persian Gulf and the Red Sea. According to the latest WHO data published in 2020 Liver Cancer Deaths in Saudi Arabia reached 845 or 0.63% of total deaths. The age-adjusted Death Rate is 4.82 per 100,000 of the population ranks Saudi Arabia 104^th in the world. Liver cancer is the fourth most common type of cancer in Saudi Arabia, accounting for about 7% of all cancer cases in the country. In Saudi Arabia, international pharmaceutical companies such as Roche, Pfizer, and Bayer dominate the liver cancer therapies industry.

The Saudi government has established a variety of efforts to encourage the discovery and commercialization of novel cancer therapies, including the King Abdullah International Medical Research Center and the Saudi Food and Drug Authority. Saudi Arabia's government spent 6.2 % of its GDP on healthcare in 2020.

Saudi Arabia Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

In recent years, the Saudi government has made substantial expenditures in its healthcare infrastructure, including the development of specialised cancer clinics and the execution of national cancer screening programmes. Economic diversification and reform measures to attract foreign investment are essential considerations while conducting business in Saudi Arabia. These aspects could boost Saudi Arabia's Liver Cancer Therapeutics market.

Market Restraints

Cultural and religious beliefs in Saudi Arabia can influence patients' desire to seek medical treatment for liver cancer in some situations. This can lead to delayed diagnosis and treatment, which can reduce therapy effectiveness. The risk to business is heightened by Saudi Arabia's vulnerability in the non-oil economy, which is exacerbated by COVID-19. It is also heavily reliant on foreign labour. These factors may deter new entrants into the Saudi Arabia Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

SPIMACO: This is a Saudi Arabian pharmaceutical company that develops and distributes a range of drugs, including oncology drugs. The company has a strong presence in the Middle East and North Africa region
Tabuk Pharmaceuticals: This is another Saudi Arabian pharmaceutical company that specializes in the development and manufacturing of generic drugs
Jamjoom Pharma: This is a Saudi Arabian pharmaceutical company that develops and distributes a range of drugs, including oncology drugs. The company has a portfolio of oncology therapeutics
Hikma Pharmaceuticals: This is a multinational pharmaceutical company that has a presence in Saudi Arabia. The company develops and distributes a range of drugs, including oncology drugs
Julphar Gulf Pharmaceutical Industries: This is a United Arab Emirates-based pharmaceutical company that has a presence in Saudi Arabia. The company develops and distributes a range of drugs, including oncology drugs

Recent Notable Updates

January 2023: Saudi Chemical Holding Co. inked an exclusive deal with Bioventure FZ-LLC, a subsidiary of GlobalOne Healthcare Holding, today, Jan. 31, through its pharmaceutical subsidiary AJA Pharmaceutical Industries Ltd. (AJA Pharma). During the Arab Health Exhibition 2023, the agreement was signed at the Saudi Export exhibit. AJA Pharma will receive exclusive licencing rights for the medicine "Ruxolitinib," a type of cancer drug used to treat certain forms of neoplasms, according to a Tadawul announcement.

Healthcare Policies and Reimbursement Scenarios

In Saudi Arabia, oncology therapeutics are regulated by the Saudi Food and Drug Authority (SFDA), which is responsible for regulating the safety, efficacy, and quality of drugs. The SFDA requires that all drugs, including oncology therapeutics, undergo a rigorous approval process before they can be marketed and distributed in the country. Regarding reimbursement, the Saudi Arabian government provides universal health coverage to its citizens through the Ministry of Health (MOH) and the Saudi Arabian Cooperative Insurance Company (SAICO)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.